No description available.

京都大学 / 新制・課程博士 / 博士(医科学) / 甲第23814号 / 医科博第135号 / 新制||医科||9(附属図書館) / 京都大学大学院医学研究科医科学専攻 / (主査)教授 村川 泰裕, 教授 松村 由美, 教授 森本 尚樹 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

Le récepteur de la vitamine D (VDR) est un facteur de transcription activé par la forme active de la vitamine D3. VDR est une cible thérapeutique potentielle pour de multiples pathologies telles que les maladies auto-immunes et neurodégénératives et certains cancers. VDR module l’expression de gènes par le recrutement sélectif de corégulateurs. Les données structurales disponibles à ce jour pour des complexes de récepteur nucléaire-corégulateurs sont très limitées. Cette étude se focalise sur l’architecture du complexe formé par VDR et un grand fragment du coactivateur MED1, une sous-unité du complexe Médiateur qui fait le lien entre les récepteurs nucléaires et la machinerie basale de transcription. Les résultats obtenus nous sont permis de caractériser l'interaction du récepteur avec le coactivateur et de révéler l'architecture globale du complexe. Ce travail fournit une base solide pour la détermination structurale d’autres complexes impliqués dans le contrôle de la transcription. / The vitamin D nuclear receptor (VDR) is a transcription factor activated by the biologically active form of vitamin D3. VDR is a potential candidate to treat neurodegenerative and autoimmune disorders, and cancer. VDR modulates the expression of vitamin D3-regulated genes by selective recruitment of coregulators of transcription which are, in turn, attractive targets in epigenetic-oriented drug discovery. Available structural data for receptor-coregulator complexes are limited; investigation of such complexes is highly important. The present work focuses on the architecture of the complex between VDR and a large part of the coactivator MED1, a subunit of the Mediator complex linking nuclear receptors to the basal transcription machinery. Obtained results revealed important details of the interaction, as well as the overall organization of the complex. This work provides a solid background for the structural investigation of similar complexes involved in the transcriptional control.

Les hormones thyroïdiennes jouent un rôle dans de nombreux processus métabolique tels que le développement, la croissance et le contrôle du métabolisme. Les HT se fixent sur leurs récepteurs nucléaires, les TR (TRalpha et beta). Ces TR sont des facteurs de transcription dont l’activité est contrôlée par la fixation de leur ligand, ils appartiennent à la super famille des récepteurs nucléaires d’hormone. Au cours de ma thèse je me suis intéressée aux rôles des TR dans deux contextes particuliers. Dans un premier temps, j’ai pu mettre en évidence le rôle de TRbeta dans la régulation du métabolisme hépatique via l’activation d’un gène clé ChREBP permettant la détection du glucose. Par l’utilisation d’animaux transgéniques et des systèmes in vitro, j’ai pu montrer que TRbeta régule positivement l’expression de ChREBP via le fixation sur son élément de réponse présent de le promoteur. Nous avons pu montrer que cette activation est isoforme spécifique, indépendante d’un autre récepteur nucléaire LXR. Dans un deuxième temps, j’ai montré que l’autre isoforme de TR, TRalpha est impliqué dans le développement de l’athérosclérose, une maladie cardiovasculaire. Par l’utilisation d’un modèle de souris transgénique, j’ai pu mettre en évidence que TRalpha possède à la fois un rôle anti-inflammatoire et également il est capable de stimuler l’élimination du cholestérol par les macrophages. L’absence de ce récepteur induit une augmentation du développement de la maladie ainsi que des cytokines circulantes chez la souris. Par l’utilisation d’un système in vitro, j’ai pu mettre en évidence que l’absence de TRalpha diminue l’efflux de cholestérol dans les macrophages de souris. Ces données suggèrent un nouveau rôle des HT/TR dans le développement de pathologies humaines, notamment un effet anti-inflammatoire longtemps supposer mais mis en évidence que très récemment. / Thyroid hormones (TH) play a role in many processes such as development, growth and metabolic control. HT bind to their nuclear receptors, the TR (TRalpha and beta). TRs belong to the superfamily of nuclear hormone receptors. These TRs are transcription factors whose activity is controlled by the binding of their ligand. During my PhD thesis I focused on the roles of TR in two contexts. Initially, I highlighted the role of TRbeta in the regulation of the hepatic metabolism via the activation of the key gene ChREBP, a glucose-responsive transcription factor. Using transgenic animal models and in vitro systems, I showed that TRbeta up regulates the expression of ChREBP via binding to its response element present in the promoter. I have shown that this activation is isoform specific and independent of another nuclear receptor LXR. In a second part, I demonstrated that the TRalpha isoform is involved in the development of atherosclerosis, a cardiovascular disease. Using a transgenic mice model, I observed that TRalpha has an anti-inflammatory effect and it is also able to stimulate the reverse cholesterol transport by macrophages. The absence of this receptor induces an increase in the development of the disease as well as in the level of circulating cytokines in mice. The deletion of TRalpha decreases the cholesterol efflux in bone marrow derived macrophages in vitro and it is correlated with a decrease of ABCA1 expression. All these data suggest a novel role of HT / TR in the development of human pathologies, including an anti-inflammatory role assumed, but recently demonstrated.

Although skeletal myogenesis is largely controlled by myogenic regulatory factors, epigenetic modifications have recently emerged as an essential regulatory mechanism of gene expression. Molecular regulation of stem cell differentiation is exerted through both genetic and epigenetic factors over distal enhancer regions. Understanding the mechanistic action of active or poised enhancers is therefore, imperative for the control of stem cell differentiation. Based on the genome-wide co-occurrence of different epigenetic marks in proliferating myoblasts, we have generated a chromatin state model to profile differentiation- and rexinoid-responsive histone acetylation in early myoblast differentiation. Here, we delineate the functional mode of transcription regulators during early myogenic differentiation using genome-wide chromatin state association. We define a role of transcriptional coactivator p300, when recruited by muscle master regulator MyoD, in the establishment and regulation of myogenic loci at the onset of myoblast differentiation. In addition, we reveal an enrichment of loci-specific histone acetylation at p300 associated active or poised enhancers, mainly when enlisted by MyoD. We have previously established that bexarotene, a clinically approved agonist of retinoid X receptor (RXR), promotes the specification and differentiation of skeletal muscle lineage. Hence, we investigated the genome-wide impact of rexinoids on myogenic differentiation and uncovered a new mechanism of rexinoid action, which is mediated by the nuclear receptor and largely reconciled through direct regulation of MyoD gene expression. In addition, we determined rexinoid-responsive residue-specific histone acetylation at a distinct chromatin state associated with MyoD and myogenin. Finally, through ChIP-seq and RNA-seq analyses, we have identified dystroglycan (Dag1) as a differentiation-dependent and a rexinoid-responsive model target, and we revealed a possible co-regulation of Dag1 by p300 and MyoD accompanied by enrichment of loci-specific histone acetylation. Taken together, we provide novel molecular insights into the regulation of myogenic enhancers by p300 in concert with MyoD. Furthermore, we provide novel mechanistic perceptions into the interplay between RXR signaling and chromatin states pertinent to myogenic programs in early myoblast differentiation. Our studies present a valuable insight for driving condition-specific chromatin state or enhancers pharmacologically to treat muscle-related diseases and for the identification of additional myogenic targets and molecular interactions for therapeutic development.

O espalhamento de raios X a baixo ângulo tem se mostrado uma poderosa ferramenta na ánalise estrutural de proteínas em solução. Estudos em condições próximas ao estado nativo podem ser realizados, permitindo a visualização tridimensional de proteínas ou complexos formados. A tese apresentada aborda a teoria envolvida para utilização desta ferramenta. Uma nova metodologia foi proposta para a determinação da massa molecular de proteínas em solução, utilizando apenas uma curva de SAXS em unidades arbitrárias, visto que até o momento, este procedimento era realizado em comparação com outra proteína padrão de peso molecular conhecido. Com relação à instrumentação científica, um equipamento de SAXS foi desenvolvido no Instituto de Física de São Carlos, permitindo agora que medidas de SAXS em proteínas em solução sejam realizadas no instituto. Clonagem, expressão e purificação foram realizadas para o domínio de ligação ao DNA da isoforma do receptor tireoideano humano, a caracterização experimental desta proteína foi realizada por anisotropia de fluorescência, crosslink e SAXS. Após formação do complexo DNA-proteína, F2-DBD hTR, o mesmo foi submetido a cristalização, os cristais obtidos para o complexo não apresentaram padrão de difração e modelos de baixa resolução foram gerados utilizando SAXS. Além disso, estudos de baixo ângulo foram realizados linha de SAXS do LNLS para a enzima ferredoxina redutase de leptospira interrogans e para o complexo formado por interleucina-22 e pelo receptor interleucina-22, sendo seus modelos tridimensionais resolvidos. / Small angle X-ray scattering has been proven to be a powerful tool in the structural analysis of proteins in solution. This technique permits the three-dimensional visualization of native proteins envelop at the level of nanometers. In this study we discuss the small angle X-ray scattering theory and we proposed a new methodology to determine the molecular weight of proteins in solution, using only SAXS curve in arbitrary units. Prior the development of this method, the proteins molecular weighs were calculated by comparison with another of known size, usually bovine serum albumin. We also assembled SAXS equipment at the Physics Institute of São Carlos, which will permits in house measurements; as well as the cloning, expression and purification of DBD hTR, followed by the characterization of this protein by fluorescence anisotropy, crosslink and SAXS. The DNA-protein complex, F2-DBD hTR, was subjected to crystallization assays. Although, the crystals obtained for the complex showed no pattern of diffraction we were able to generate low-resolution models for the F2-DBD hTR using SAXS analysis. Moreover, the studies of the protein LepFNR and the complex IL-22/IL-22R1 by small angle X-ray scattering were performed in the line of SAXS of the LNLS, and their threedimensional models were resolved

Prostate cancer (PC) is characterised by dependence upon androgen receptor (AR) as its driving oncogene. When organ-confined, radical treatment can be curative, however there is no cure for advanced, castration-resistant prostate cancer (CRPC). There is therefore a need to better understand the biology of PC, and how influencing AR can modify disease progression. Estrogen is essential for prostate carcinogenesis with evidence from epidemiological, in vitro, human tissue and animal studies. Most suggests that estrogen receptor beta (ERβ) is tumour-suppressive, but trials of ERβ-selective agents have not improved clinical outcomes. ERβ has also been implicated as an oncogene, therefore its role remains unclear. Additional evidence suggests interplay between ERβ and AR, the mechanisms of which are uncertain. The study hypothesis ‘ERβ is an important modulator of prostate carcinogenesis’ was developed to establish whether targeting ERβ could affect PC progression. Much of the confusion around ERβ stems from use of inadequately validated antibodies and cell line models. The first phase of this work was to test ERβ antibodies using an ERβ-inducible cell system. Eight ERβ antibodies were assessed by multiple techniques, showing that commonly used antibodies are either non-specific or only specific in one modality. Two reliable antibodies were identified. Next, cell lines previously used to study ERβ were assessed using validated antibodies and independent approaches. No ERβ expression was detected; an important finding that casts doubt on previously published ERβ biology. Subsequently, a PC cell line with inducible ERβ expression (LNCaP-ERβ) was developed and validated to enable controlled experiments on the effects of ERβ on proliferation, gene expression and ERβ/AR genomic cross-talk. Phase three of this work focused on ERβ biology in PC and its relationship to AR. Interrogation of clinical datasets showed that greater ERβ expression associated with favourable prognosis. Gene expression data from men treated with androgen deprivation therapy revealed that AR represses ERβ. This was confirmed in vitro. The LNCaP-ERβ cell line was treated with androgen and/or ERβ-selective estrogen. Activated ERβ in the presence of androgen-stimulated AR inhibited cell proliferation and down-regulated androgen-dependent genes. Genome-wide mapping of ERβ binding sites reveals that ERβ antagonises AR through competition for shared DNA binding sites. In conclusion, ERβ expression is down-regulated by AR during malignant transformation of prostate epithelium. We reveal an antagonistic relationship between ERβ and AR whereby sustaining or replacing ERβ may inhibit tumour growth through down-regulation of AR-target genes. In future, an ERβ-selective compound may be used to slow or abrogate PC progression.

Os receptores nucleares são de suma importância para os processos de sinalização intercelular nos eucariotos, uma vez que possuem a capacidade de convergir diferentes sinais internos e externos na regulação de programas genéticos. Estas proteínas funcionam, na sua maioria, como fatores de transcrição ativados por ligantes, sendo a via de comunicação direta entre as moléculas de sinalização e a resposta transcricional eliciada pelas mesmas. A programação genética, estabilizada ou modificada pelos receptores, afeta virtualmente todos os aspectos da vida dos organismos multicelulares, tais como a embriogênese, a homeostase, a reprodução, o crescimento e a morte celular. A regulação transcricional e a seletividade promovida por estas proteínas têm fomentado intensas pesquisas, as quais estão decifrando a complexa rede de eventos moleculares que relatam sua forma de ação. Será um desafio para o futuro o conhecimento completo das regras moleculares que definem sua maneira de promover o controle espacial e temporal da expressão gênica. Estas informações prometem trazer detalhes cruciais para o desenvolvimento de drogas mais eficientes e de grande valor terapêutico. Neste contexto, o principal objetivo dos estudos aqui apresentados foi o de aumentar o conhecimento sobre o comportamento e estrutura do receptor nuclear humano dos hormônios tireoidianos, isoforma β1 (hTRβ1), e do receptor nuclear humano do ácido retinóico 9-cis, isoforma ? (hRXRα). Para tal, aplicou-se a técnica de espalhamento de raios X a baixos ângulos para determinar-se, em solução, o envelope destes receptores contendo os domínios de ligação ao DNA e ao ligante. Paralelamente, investiu-se em diversas tentativas de cristalização dos mesmos. Os resultados obtidos permitiram a determinação da localização espacial dos diferentes domínios e as organizações quaternárias dos homodímeros e homotetrâmeros. Conseqüentemente, foram propostos os primeiros modelos estruturais de receptores nucleares contendo os domínios de ligação ao DNA e ao ligante. O comportamento oligomérico, em solução, do hTRβ1 também foi analisado qualitativamente. Verificou-se que a formação do homodímero e do homotetrâmero é influenciada pela presença do hormônio T3, pela concentração protéica, pelos domínios presentes e por mutações específicas. Estes estudos geraram a hipótese de que o receptor nuclear hTRβ1 é capaz de se autoreprimir. Até então, dentro da superfamília dos receptores nucleares, esta capacidade de autorepressão somente havia sido descrita para o receptor hRXRα. Por fim, cristalizou-se o domínio LBD do receptor hTRβ1 com os ligantes T3, Triac e GC-1. O objetivo foi o de determinar estruturas cristalográficas importantes para o futuro desenvolvimento de tiromiméticos de ação isoforma-seletiva. / In eukaryotes, nuclear receptors are of major importance for intercellular signaling because they join different intra and extracellular signals during regulation of genetic programs. The great majority of these proteins function as ligand activated transcription factors providing a direct link between signaling molecules and the transcriptional responses elicited by them. The genetic programs that these receptors establish or modify affect virtually all aspects of the multicellular organisms? life, such as embryogenesis, homeostasis, reproduction, cell growth, and death. Their gene-regulatory power and selectivity has prompted intense research which is now starting to decipher the complex network of molecular events involved in transcription regulation. The future challenge will be to uncover the molecular rules that define spatial and temporal control of gene expression. Such knowledge would be essential to the development of more efficient drugs with better therapeutic values. Therefore, the main purpose in this study was to extend the understanding on the behavior and the structure of human thyroid receptor, isoform ?1 (hTRβ1), and human retinoic acid X receptor, isoform ? (hRXRα). It was applied the small angle X-ray scattering technique to determine, in solution, the envelop of both receptors containing DNA and ligand binding domains. Beside this, several crystallization conditions were tried for both receptors. The results made possible to define the spatial localization of the domains and the quaternary structure of the homodimers and homotetramers. Consequently, we were able to propose the first structural models for nuclear receptors containing the DNA and ligand binding domains. The oligomeric behavior of the hTRβ1, in solution, was also analyzed qualitatively. We verified that it was influenced by the presence of T3 hormone, the protein concentration, the presence of both DNA and ligand binding domains, and by specific mutations. Based on these results, we were able to hypothesize that the hTRβ1 has the capacity of autorepression. Up to now, only the hRXRα, in the whole nuclear receptor superfamily, had been described to behave similarly. Finally, we crystallized the ligand binding domain of the hTRβ1 in the presence of the ligands T3, Triac, and GC-1. The objective was to solve crystallographic structures essential for the future development of tiromimetics with isoform-selective action.

Les œstrogènes sont impliqués dans le développement et l'homéostasie de nombreux tissus reproducteurs et extra-reproducteurs et influencent de nombreux processus physiologiques et pathologiques. L'action des œstrogènes est relayée majoritairement par le récepteur des œstrogènes ERα dont l'action nucléaire conduit à la régulation transcriptionnelle de ses gènes cibles alors que son activation membranaire induit différentes voies de signalisations cytoplasmiques. Le but de ce travail de thèse a été d'évaluer in vivo les rôles respectifs des effets nucléaires et membranaires dans différents processus physiologiques (modulation de la fertilité, vasculo-protection, prolifération endométriale) ou pathologiques (angiogenèse tumorale) en réponse au 17β-œstradiol (E2). Différents modèles de souris transgéniques ont été utilisés, notamment les souris C451A-ERα présentant une mutation du site de palmitoylation nécessaire à l'adressage membranaire de ERα. Nous avons ainsi pu mettre en évidence la part respective des effets membranaires et nucléaires de ERα dans différents tissus. / Estrogen Receptor ERα is a nuclear receptor, which regulates many physiological functions through estradiol (E2) binding on two cellular sub-localizations: Nuclear ERa is implicated in the regulation of gene expression while membrane ERα (targeting through Cys451 palmitoylation) activates kinase signaling. The main objective of my PhD thesis was to investigate the respective roles of membrane and nuclear ERα signaling in physiological functions (fertility, vascular protection, uterine proliferation) or pathological functions (tumoral angiogenesis) in response to 17β-estradiol, pharmacological tools (EDC, Estrogen Dendrimer Conjugate) or selective ligand as tamoxifen or Estetrol (E4). Two complementary mouse models were used to delineate their respective functions of membrane and nuclear ERa signaling in vivo: ERα-AF20 mice with specific deletion of the AF2 transactivation function necessary to recruit transcriptional coactivators; C451A-ERα mice with specific mutation of the palmitoylation site of ERα necessary for membrane targeting. Furthermore, the specific role of ERα methylation, occurring on Arg264 and essential for ERα/Src/PI3K complex formation, has been evaluated in vivo using mice R264A-ERα. This work demonstrates for the first time the respective role of membrane and nuclear ERα signaling in vivo. We have highlighted some tissue-specific roles of nuclear and membrane signaling in uterus and vascular protection respectively, but also in fertility. These findings contribute to a better understanding of the molecular ERα signaling in vivo which is of major importance for the design of new SERMs (Selective ER Modulators).

FoxO proteins are transcriptional factors acting downstream of the tumor suppressor PTEN. Their activity is negatively regulated by AKT-mediated phosphorylation. Our previous studies showed a mutual suppression between PTEN and the androgen receptor (AR) in regulating growth and apoptosis in prostate cancer (PCa) cells. We hypothesize that nuclear FoxO proteins are involved in mediating this mutual antagonism. In this dissertation, we report that PTEN inhibits AR activity through FoxO1 and provide evidence for the involvement of FoxO factors in the androgen-mediated suppression of PTEN-induced apoptosis. Our studies identify a novel mechanism for AR inhibition by FoxO1 and demonstrated the participation of FoxO1 in AR inhibition by PTEN. Ectopic expression of active FoxO1 decrease the transcriptional activity of the AR as well as androgen-induced cell proliferation and production of prostate-specific antigen in PCa cells. FoxO1 knock down by RNA interference increased the transcriptional activity of the AR in PTEN intact cells and relieved its inhibition by ectopic PTEN in PTEN null cells. Mutational analysis revealed that FoxO1 region 150-655, which contains the fork head box and C-terminal activation domain, was required for AR inhibition. Mammalian two-hybrid assays demonstrated that the inhibition of AR activity by PTEN through FoxO1 involved the interference of androgen-induce interaction of the N- and C- termini of the AR and the recruitment of the p160 coactivators to the AR N-terminus. In addition to the inhibition of AR by FoxO1, we also demonstrated that PTEN-induced apoptosis is mediated through FoxO factors and that AR inhibited FoxO1 activity by yet-to-be identified downstream target gene. Mutation of AR DNA binding domain partially relieved the inhibition of FoxO1 trasnscriptional activity by androgens. Inhibiton of new protein synthesis abolished the AR-mediated decrease in the mRNA level of FoxO1 target gene. Overall, these studies reveal novel mechanisms for the mutual inhibition of AR and FoxO1 activity and establish FoxO proteins as important nuclear factors that mediate the mutual antagonism between AR and PTEN tumor suppressor in PCa cells.